A randomized phase II trial of TSU-68 in combination with TS-1 and CDDP versus TS-1 and CDDP in patients with advanced gastric cancer

Trial Profile

A randomized phase II trial of TSU-68 in combination with TS-1 and CDDP versus TS-1 and CDDP in patients with advanced gastric cancer

Completed
Phase of Trial: Phase II

Latest Information Update: 24 May 2016

At a glance

  • Drugs Orantinib (Primary) ; Cisplatin; Gimeracil/oteracil/tegafur
  • Indications Gastric cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 17 Sep 2013 Results published in the British Journal of Cancer.
    • 01 Feb 2013 New trial record
    • 26 Jan 2013 Primary endpoint 'Progression-free-survival-duration' has not been met.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top